Intercept Pharmaceuticals Inc (ICPT) Receives Consensus Rating of “Hold” from Analysts

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has been assigned an average rating of “Hold” from the twenty-five brokerages that are covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and ten have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $127.06.

Several analysts have recently weighed in on ICPT shares. Cantor Fitzgerald upgraded Intercept Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $69.00 price target on the stock in a report on Wednesday, November 1st. Deutsche Bank started coverage on Intercept Pharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $106.00 price target on the stock. Credit Suisse Group set a $167.00 price target on Intercept Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, January 22nd. BidaskClub cut Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 16th. Finally, Wedbush restated a “buy” rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, January 5th.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at $53.29 on Friday. The firm has a market capitalization of $1,457.93, a PE ratio of -3.60 and a beta of -2.13. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. Intercept Pharmaceuticals has a twelve month low of $51.53 and a twelve month high of $135.59.

Several institutional investors have recently bought and sold shares of ICPT. Alliancebernstein L.P. lifted its stake in shares of Intercept Pharmaceuticals by 6.2% in the second quarter. Alliancebernstein L.P. now owns 9,459 shares of the biopharmaceutical company’s stock worth $1,145,000 after acquiring an additional 550 shares during the period. Teachers Advisors LLC lifted its stake in shares of Intercept Pharmaceuticals by 16.1% in the second quarter. Teachers Advisors LLC now owns 18,430 shares of the biopharmaceutical company’s stock worth $2,231,000 after acquiring an additional 2,559 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Intercept Pharmaceuticals by 23.3% in the second quarter. PNC Financial Services Group Inc. now owns 2,490 shares of the biopharmaceutical company’s stock worth $302,000 after acquiring an additional 470 shares during the period. New York State Common Retirement Fund lifted its stake in shares of Intercept Pharmaceuticals by 13.5% in the second quarter. New York State Common Retirement Fund now owns 40,300 shares of the biopharmaceutical company’s stock worth $4,879,000 after acquiring an additional 4,799 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Intercept Pharmaceuticals by 14.9% in the second quarter. Northern Trust Corp now owns 84,983 shares of the biopharmaceutical company’s stock worth $10,289,000 after acquiring an additional 10,993 shares during the period. 74.37% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Intercept Pharmaceuticals Inc (ICPT) Receives Consensus Rating of “Hold” from Analysts” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/09/intercept-pharmaceuticals-inc-icpt-receives-consensus-rating-of-hold-from-analysts.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply